Skip to content
2000
Volume 20, Issue 3
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Introduction

Non-profit clinical trials submitted for authorization over three years to the Clinical Trials Office of the Italian Medicines Agency were reviewed and critically analyzed.

Objective

The objectives are to highlight potential trends following the full implementation of Regulation (EU) No. 536/2014 and to reveal the different nuances of non-profit clinical trials, comparing them with the general profile of all clinical trials.

Methods

Using a multidisciplinary approach, the research navigates public data, official documents and data retrieved from the Italian National Observatory on Clinical Trials and from the European Clinical Trials Information System to reveal shifts in the clinical trials landscape.

Results

A decrease in non-profit applications submitted in the 2020-2022 timeframe is emerging, clearly related to the new regulatory complexities and uncertainties in the adoption of the Clinical Trials Information System platform. Results also show a divergence between non-profit and overall clinical trials in terms of authorization outcomes, also including studies with a COVID-19 indication. Further comparing non-profit studies with the total number of clinical trials across different characteristics, such as phases, therapeutic areas and study purposes, increases transparency and availability of insight information.

Conclusion

Relevant data are provided as a result of the review and analysis of non-profit clinical trials, highlighting specific features. Overall, this critical analysis provides an overview of recent trends and, also promotes insights for further consideration by regulators to adequately support clinical research in a complex and evolving regulatory environment.

Loading

Article metrics loading...

/content/journals/rrct/10.2174/0115748871310179250109065608
2025-01-31
2025-12-18
Loading full text...

Full text loading...

References

  1. Ministerial Decree of 30 November 2021, Measures to facilitate and support the implementation of non-profit clinical trials of medicinal products and observational studies and to regulate the transfer of data and results of non-profit trials for registration purposes, pursuant to art. 1, paragraph 1, letter c), of the Legislative Decree of 14 May.2021Available From: https://www.gazzettaufficiale.it/eli/id/2022/02/19/22A01189/sg
  2. AIFA website. 20th National Report on Clinical Trials of Medicines in Italy 2023.2023Available From: https://www.aifa.gov.it/-/20-rapporto-nazionale-sulla-sperimentazione-clinica-dei-medicinali-in-italia-2023
  3. Clinical Trials Information System (CTIS) interface.Available From: https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en
  4. AIFA website. Osservatorio nazionale Sperimentazione Clinica (OsSC).Available From: https://www.aifa.gov.it/osservatorio-nazionale-sperimentazione-clinica
  5. Regulation (EU) No. 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance.2014Available From: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32014R0536
  6. AIFA website. Open Data delle Sperimentazioni Cliniche Farmacologiche (SC) presenti in OsSC dal secondo semestre del 2018.2018Available From: https://www.aifa.gov.it/en/sperimentazioni-cliniche
  7. Legislative Decree 24 June 2003, n. 211, Implementation of Directive 2001/20/EC on the application of good clinical practice in the conduct of clinical trials of medicinal products for clinical use, Official Journal General Series n.184 of 09 August 2003 - Ordinary Supplement n. 130.2003Available From: https://www.gazzettaufficiale.it/eli/id/2003/08/09/003G0229/sg
  8. Law 11 January 2018, n. 3, Delegation to the Government on clinical trials of medicinal products as well as provisions for the reorganization of health professions and for the health management of the Ministry of Health. (18G00019) (GU General Series n.25 of 31-01-2018).2018Available From: https://www.gazzettaufficiale.it/eli/id/2018/1/31/18G00019/sg
  9. Legislative Decree 14 May 2019, n. 52, Implementation of the delegation for the reorganisation and reform of the legislation on clinical trials of medicinal products for human use, pursuant to Article 1, paragraphs 1 and 2, of Law 11 January 2018, n. 3. (19G00059) (GU General Series n.136 of 12-06-2019).2019Available From: https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2019-06-12&atto.codiceRedazionale=19G00059&elenco30giorni=true
  10. Ministerial Decree 1 February 2022 Identification of national ethics committees. (22A01630) (GU General Series n.63 of 16-03-2022).2022Available From: https://www.gazzettaufficiale.it/eli/id/2022/03/16/22A01630/sg
  11. Ministerial Decree 26 January 2023, Identification of forty territorial ethics committees. (23A00852) (GU General Series n.31 of 07-02-2023).2023Available From: www.gazzettaufficiale.it/eli/id/2023/02/07/23A00852/sg
  12. Ministerial Decree of 27 January 2023, Regulation of the transitional phase pursuant to Article 2, paragraph 15, of Law 11 January 2018, no. 3, in relation to the evaluation activities and methods of interaction between the Coordination Centre, the territorial ethics committees, the national ethics committees and the Italian Medicines Agency. (23A00851) (GU General Series no. 31 of 07-02-2023).2023Available From: https://www.gazzettaufficiale.it/eli/id/2023/02/07/23A00851/SG
  13. Ministerial Decree of 30 January 2023, Determination of the single fee for clinical trials, the attendance fee and the reimbursement of expenses for participation in the meetings of the National Coordination Centre of the Territorial Ethics Committees for Clinical Trials on Medicinal Products for Human Use and Medical Devices, of the Territorial Ethics Committees and of the National Ethics Committees. (23A00850) (GU General Series no. 31 of 07-02-2023).2023Available From: https://www.gazzettaufficiale.it/eli/id/2023/02/07/23A00850/sg
  14. FADOI’s Manifesto2023Available From: https://www.fadoi.org/wp-content/uploads/2023/09/FADOI_Manifesto-Ricerca-2023.pdf
  15. del ÁlamoM. BührerC. FisherD. GrieseM. LingorP. PalladiniG. SireauN. HivertV. SangiorgiL. GuillotF. HalftermeyerJ. SouckováL. NoskováK. DemlováR. Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: An analysis of six use cases.Trials202223178310.1186/s13063‑022‑06713‑y36109818
    [Google Scholar]
  16. AIFA website. Technical and advisory committees.Available From: https://www.aifa.gov.it/en/commissioni-tecnico-consultive#:~:text=Commissione%20Tecnico%20Scientifica%20(CTS),determina%20il%20rapporto%20costo%2Defficacia
  17. EMA, European Medicines Agency. A call to pool EU research resources into large-scale, multi-centre, multi-arm clinical trials against COVID-19.Available From: https://www.ema.europa.eu/en/documents/other/call-pool-eu-research-resources-large-scale-multi-centre-multi-arm-clinical-trials-against-covid-19_en.pdf
    [Google Scholar]
  18. EMA, European Medicines Agency website. Multinational clinical trials by non-commercial sponsors.Available From: https://accelerating-clinical-trials.europa.eu/our-work/multinational-clinical-trials-non-commercial-sponsors_en
/content/journals/rrct/10.2174/0115748871310179250109065608
Loading
/content/journals/rrct/10.2174/0115748871310179250109065608
Loading

Data & Media loading...


  • Article Type:
    Research Article
Keyword(s): authorization outcomes; Clinical trials; COVID-19; non-commercial; non-profit; regulatory
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test